Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1924-1931

  Ohashi, Toya ^a   Iizuka, Sayoko ^a   Shimada, Yohta ^a   Higuchi, Takashi ^a   Eto, Yoshikatsu ^a   Ida, Hiroyuki ^a   Kobayashi, Hiroshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; CD3 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT HUMAN ALPHA GLUCOSIDASE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; T CELL DEPLETION; T LYMPHOCYTE;

ANIMALIA; MUS;

EID: 84866984376     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.133     Document Type: Article

References (32)

1. Kishnani, PS, Corzo, D, Nicolino, M, Byrne, B, Mandel, H, Hwu, WL et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefts in infantile-onset Pompe disease. Neurology 68: 99-109.
2. Kishnani, PS, Hwu, WL, Mandel, H, Nicolino, M, Yong, F and Corzo, D; Infantile-Onset Pompe Disease Natural History Study Group (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148: 671-676.
3. van der Ploeg, AT, Clemens, PR, Corzo, D, Escolar, DM, Florence, J, Groeneveld, GJ et al. (2010). A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362: 1396-1406.
4. Raben, N, Danon, M, Gilbert, AL, Dwivedi, S, Collins, B, Thurberg, BL et al. (2003). Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80: 159-169.
5. Amalftano, A, Bengur, AR, Morse, RP, Majure, JM, Case, LE, Veerling, DL et al. (2001). Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132-138.
6. Kishnani, PS, Nicolino, M, Voit, T, Rogers, RC, Tsai, AC, Waterson, J et al. (2006). Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149: 89-97.
7. Kishnani, PS, Goldenberg, PC, DeArmey, SL, Heller, J, Benjamin, D, Young, S et al. (2010). Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99: 26-33.
8. de Vries, JM, van der Beek, NA, Kroos, MA, Ozkan, L, van Doorn, PA, Richards, SM et al. (2010). High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101: 338-345.
9. Banugaria, SG, Prater, SN, Ng, YK, Kobori, JA, Finkel, RS, Ladda, RL et al. (2011). The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13: 729-736.
10. Joseph, A, Munroe, K, Housman, M, Garman, R and Richards, S (2008). Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 152: 138-146.
11. Mendelsohn, NJ, Messinger, YH, Rosenberg, AS and Kishnani, PS (2009). Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 360: 194-195.
12. Messinger, YH, Mendelsohn, NJ, Rhead, W, Dimmock, D, Hershkovitz, E, Champion, M et al. (2012). Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14: 135-142.
13. Rohrbach, M, Klein, A, Köhli-Wiesner, A, Veraguth, D, Scheer, I, Balmer, C et al. (2010). CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33: 751-757.
14. Chu, Q, Moreland, RJ, Gao, L, Taylor, KM, Meyers, E, Cheng, SH et al. (2010). Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery. Mol Ther 18: 2146-2154.
15. Douillard-Guilloux, G, Richard, E, Batista, L and Caillaud, C (2009). Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med 11: 279-287.
16. van Til, N P, Stok, M, Aerts Kaya, FS, de Waard, MC, Farahbakhshian, E, Visser, TP et al. (2010). Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 115: 5329-5337.
17. Ohashi, T, Iizuka, S, Shimada, Y, Eto, Y, Ida, H, Hachimura, S et al. (2011). Oral administration of recombinant human acid a-glucosidase reduces specifc antibody formation against enzyme in mouse. Mol Genet Metab 103: 98-100.
18. Sun, B, Bird, A, Young, SP, Kishnani, PS, Chen, YT and Koeberl, DD (2007). Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 81: 1042-1049.
19. Sun, B, Kulis, MD, Young, SP, Hobeika, AC, Li, S, Bird, A et al. (2010). Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther 18: 353-360.
20. Sun, B, Li, S, Bird, A, Yi, H, Kemper, A, Thurberg, BL et al. (2010). Antibody formation and mannose-6-phosphate receptor expression impact the effcacy of muscle-specifc transgene expression in murine Pompe disease. J Gene Med 12: 881-891.
21. Lipinski, SE, Lipinski, MJ, Burnette, A, Platts-Mills, TA and Wilson, WG (2009). Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98: 319-321.
22. +-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 113: 193-203.
23. Ohashi, T, Iizuka, S, Ida, H and Eto, Y (2008). Reduced alpha-Gal A enzyme activity in Fabry fbroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94: 313-318.
24. Ohashi, T, Sakuma, M, Kitagawa, T, Suzuki, K, Ishige, N and Eto, Y (2007). Infuence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92: 271-273.
25. Belghith, M, Bluestone, JA, Barriot, S, Mégret, J, Bach, JF and Chatenoud, L (2003). TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208.
26. You, S, Leforban, B, Garcia, C, Bach, JF, Bluestone, JA and Chatenoud, L (2007). Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 104: 6335-6340.
27. Banati, M, Hosszu, Z, Trauninger, A, Szereday, L and Illes, Z (2011). Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease. Muscle Nerve 44: 720-726.
28. Sherry, N, Hagopian, W, Ludvigsson, J, Jain, SM, Wahlen, J, Ferry, RJ Jr et al.; Protégé Trial Investigators. (2011). Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378: 487-497.
29. Baumgart, DC, Targan, SR, Dignass, AU, Mayer, L, van Assche, G, Hommes, DW et al. (2010). Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Infamm Bowel Dis 16: 620-629.
30. van der Woude, CJ, Stokkers, P, van Bodegraven, AA, Van Assche, G, Hebzda, Z, Paradowski, L et al.; Initiative on Crohn's and Colitis, The Netherlands. (2010). Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Infamm Bowel Dis 16: 1708-1716.
31. Kuhn, C, You, S, Valette, F, Hale, G, van Endert, P, Bach, JF et al. (2011). Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med 3: 68ra10.
32. Kyosen, SO, Iizuka, S, Kobayashi, H, Kimura, T, Fukuda, T, Shen, J et al. (2010). Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 17: 521-530.